SEC Form D private-offering filing
TenNor Therapeutics (Suzhou) Ltd
A new SEC Form D private-offering notice from Suzhou, a $14,699,667 filer-stated offering target in Biotech. The source filing is one click away.
Suzhou, China based clinical stage biotech developing therapies for bacterial infection and metabolic disease, including its lead H. pylori drug candidate rifasutenizol.
Filed 2026-05-26Filed to raise $14,699,667First money in 2026-05-12Raised so far $14,699,667HQ (as filed) SuzhouSector Biotech ✓Stage (inferred) EarlyCall status Non-US principal office
Source linked the Form D on EDGAR↗Website verified tennortherapeutics.com↗Named in the filing 11 executives & directors
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.